Raymond James Financial Services Advisors’s Juno Therapeutics, Inc. JUNO Stock Holding History

Raymond James Financial Services Advisors’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-13,463	Closed	-$615K	–	2814
2017 Q4	$615K	Buy	13,463 +2,098	+18%	+$105K	﹤0.01%	1590
2017 Q3	$510K	Buy	+11,365	New	+$387K	﹤0.01%	1701
2016 Q4	–	Sell	-9,191	Closed	-$276K	–	2485
2016 Q3	$276K	Buy	9,191 +320	+4%	+$9.96K	﹤0.01%	1846
2016 Q2	$341K	Buy	8,871 +804	+10%	+$33.4K	﹤0.01%	1641
2016 Q1	$307K	Buy	+8,067	New	+$281K	﹤0.01%	1537
2015 Q4	–	Sell	-10,830	Closed	-$441K	–	1656
2015 Q3	$441K	Buy	+10,830	New	+$475K	0.01%	1109

Other funds holding JUNO

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM

Raymond James Financial Services Advisors's JUNO Position: Q1 2018 in Review

Raymond James Financial Services Advisors sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 13,463 shares — an estimated $615K sold.

Raymond James Financial Services Advisors first reported a position in JUNO in Q3 2015 and held it in 6 quarters. The position peaked at $615K in Q4 2017. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

Raymond James Financial Services Advisors reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
Raymond James Financial Services Advisors sold 13,463 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $615K.
Raymond James Financial Services Advisors first reported a position in Juno Therapeutics, Inc. in Q3 2015 and held it in 6 quarters.
Raymond James Financial Services Advisors's Juno Therapeutics, Inc. position peaked at $615K in Q4 2017.
2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Raymond James Financial Services Advisors's 13F filing for Q1 2018, filed 16 Apr 2018.